108
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d5823554e245">Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. </p>

          Related collections

          Author and article information

          Journal
          New England Journal of Medicine
          N Engl J Med
          Massachusetts Medical Society
          0028-4793
          1533-4406
          April 14 2019
          April 14 2019
          Affiliations
          [1 ]From the George Institute for Global Health, University of New South Wales Sydney (V.P., M.J.J., B.N., S. Bompoint), the Royal North Shore Hospital (V.P.), Concord Repatriation General Hospital (M.J.J.), and the Charles Perkins Centre, University of Sydney (B.N.), Sydney, and the Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St. Leonards, NSW (C.P.) — all in Australia; Imperial College London (B.N.) and the Department of Renal Medicine,...
          Article
          10.1056/NEJMoa1811744
          30990260
          a3584a12-c083-448c-b9d6-084ee4c78947
          © 2019
          History

          Comments

          Comment on this article